The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for game-changing treatments and impressive returns is certain, the linked risks copyright are also consid